Tobramycin sulfate cas no:49842-07-1
Synonyms: Tobramitsetin;Tobramycine [INN-French];Tobrasone;Obramycin;(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4))-2-deoxy-;Tenemicin;D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-;Gotabiotic;Tobramicina [INN-Spanish];Brulamycin;3-Deoxykanamycin B;Tobramycinum [INN-Latin];Nebramycin factor 6;Tobradistin;Lilly 47663;Tobacin;Deoxykanamycin B;Nebramycin VI;Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-tyrideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-;Tobramicin;4-(2,6-Diamino-2,3,6-trideoxy-alpha-D-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-D-glycopyranosyl)-2-deoxystreptamine;Tobramaxin;Tobralex;Obracin;Nebramycin 6;
NameTobramycin sulfate
CAS49842-07-1
SynonymsTobramitsetin;Tobramycine [INN-French];Tobrasone;Obramycin;(2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4))-2-deoxy-;Tenemicin;D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-;Gotabiotic;Tobramicina [INN-Spanish];Brulamycin;3-Deoxykanamycin B;Tobramycinum [INN-Latin];Nebramycin factor 6;Tobradistin;Lilly 47663;Tobacin;Deoxykanamycin B;Nebramycin VI;Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-tyrideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-;Tobramicin;4-(2,6-Diamino-2,3,6-trideoxy-alpha-D-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-D-glycopyranosyl)-2-deoxystreptamine;Tobramaxin;Tobralex;Obracin;Nebramycin 6;
EINECS(EC#)256-499-2
Molecular FormulaC18H37N5O9.H2O4S
Molecular Weight1154.16
storage temp2-8°C
Hazard T: Toxic;
Risk R61
Safety
Hazard Codes: T .gif)
Risk Statements: 61-20/21/22
60: Tobramycin sulfate (49842-07-1) may impair fertility
20/21/22: Harmful by inhalation, in contact with skin and if swallowed
Safety Statements: 53-22-36/37/39-45
53: Avoid exposure - obtain special instruction before use
22: Do not breathe dust
45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
36/37/39: Wear suitable protective clothing, gloves and eye/face protection
WGK Germany: 3
|
Organism
|
Test Type
|
Route
|
Reported Dose (Normalized Dose)
|
Effect
|
Source
|
|
mouse
|
LD50
|
intraperitoneal
|
262mg/kg (262mg/kg)
|
autonomic nervous system: other (direct) parasympathomimetic
behavioral: convulsions or effect on seizure threshold
lungs, thorax, or respiration: dyspnea
|
Antibiotiki. Vol. 24, Pg. 60, 1979.
|
|
mouse
|
LD50
|
intravenous
|
77mg/kg (77mg/kg)
|
autonomic nervous system: other (direct) parasympathomimetic
behavioral: convulsions or effect on seizure threshold
lungs, thorax, or respiration: dyspnea
|
Antibiotiki. Vol. 24, Pg. 60, 1979.
|
|
mouse
|
LD50
|
oral
|
> 10500mg/kg (10500mg/kg)
|
|
Antibiotiki. Vol. 24, Pg. 60, 1979.
|
|
mouse
|
LD50
|
subcutaneous
|
560mg/kg (560mg/kg)
|
autonomic nervous system: other (direct) parasympathomimetic
behavioral: convulsions or effect on seizure threshold
lungs, thorax, or respiration: dyspnea
|
Antibiotiki. Vol. 24, Pg. 60, 1979.
|
|
rat
|
LD50
|
intravenous
|
126mg/kg (126mg/kg)
|
autonomic nervous system: other (direct) parasympathomimetic
behavioral: convulsions or effect on seizure threshold
lungs, thorax, or respiration: dyspnea
|
Antibiotiki. Vol. 24, Pg. 60, 1979.
|
|
rat
|
LD50
|
subcutaneous
|
1680mg/kg (1680mg/kg)
|
autonomic nervous system: other (direct) parasympathomimetic
behavioral: convulsions or effect on seizure threshold
lungs, thorax, or respiration: dyspnea
|
Antibiotiki. Vol. 24, Pg. 60, 1979.
|
|
women
|
LDLo
|
intravenous
|
15mg/kg/5D-I (15mg/kg)
|
behavioral: wakefulness
behavioral: "hallucinations, distorted perceptions"
|
JAMA, Journal of the American Medical Association. Vol. 247, Pg. 1319, 1982.
|
